FDA’s GRAS Glow-Up

For decades, the GRAS process has operated a bit like the honor system at a highway fruit stand: companies could determine that an ingredient was Generally Recognized as Safe (GRAS) and, if they chose, tell FDA about it. Many did. Some did not. FDA now wants everyone to show their work.

 

On August 10, 2026, FDA proposed a rule that would convert its voluntary GRAS notification program into a mandatory one, requiring manufacturers to notify the agency when they conclude that a substance added to human or animal food is GRAS under its intended conditions of use.

 

What’s Changing?

 

Today, a company can reach a GRAS conclusion without submitting anything to FDA. Under the proposed rule, that would largely disappear.

 

Instead, FDA would require notification for most GRAS determinations, expand its public GRAS inventory, and gain visibility into substances entering the food supply that may never have crossed the agency’s desk before.

 

For ingredients already on the market under historical self-GRAS determinations, FDA is proposing a streamlined transition pathway rather than forcing immediate full submissions for every existing use.

 

Why Industry Should Pay Attention

 

This proposal is about more than paperwork.

 

It represents a fundamental policy shift from “you may tell FDA” to “you must tell FDA.” The agency has made clear that it wants greater transparency into food ingredients and increased oversight of substances entering the marketplace.

 

For food manufacturers, ingredient suppliers, packaging companies, and emerging food-tech businesses, that could mean:

• More regulatory scrutiny of ingredient safety files;
• Greater pressure to maintain robust scientific support for GRAS conclusions;
• Increased public visibility into ingredient submissions; and
• Possible impacts on product development timelines and launch strategies.

 

In short, companies that have treated GRAS dossiers as something that only sees daylight during due diligence may soon find FDA asking for a closer look.

 

The Bigger Picture

 

The proposed rule fits squarely within FDA’s and HHS’s broader focus on ingredient transparency, food safety, and oversight of food additives and ultra-processed foods. Whether one views the proposal as a long-overdue modernization effort or unnecessary regulatory expansion, the direction is unmistakable: FDA wants to know more about what’s in the food supply before learning about it from a news headline.

 

 

What Companies Should Do Now

The comment period remains open until December 9, 2026.

 

Between now and then, companies should consider:

• Identifying products supported by self-GRAS determinations;
• Evaluating whether existing GRAS files are FDA-ready;
• Reviewing supplier and contractual obligations regarding regulatory responsibility; and
• Considering whether to submit comments addressing implementation challenges, confidentiality concerns, or transition requirements.

 

Our Takeaway

 

The headline here is not that FDA is eliminating GRAS. It is eliminating the ability for most GRAS conclusions to remain invisible.

 

If finalized, the proposal could become the most consequential FDA ingredient regulation in years, particularly for companies that have relied on self-GRAS determinations to move quickly and innovate. Businesses that inventory their GRAS determinations and strengthen their scientific support now will likely be in a far better position than those scrambling after a final rule arrives.

 

As always, when FDA says “trust us,” it is usually a good time to make sure your documentation says “trust us, and here’s the data.”

 

For questions on the proposed rule, GRAS determinations, ingredient reviews, food additive requirements, submitting comments to FDA or for support with strategic FDA compliance and enforcement, please contact info@garg-law.com.